Pharmaceutical Technology

JUNE 24, 2025

In the Research & Development category, i3 Membrane was honored for its efforts to scale DMC for commercial therapeutic drug manufacturing, demonstrating superior performance and efficiency. This preservation of molecular quality is vital for ensuring the safety and effectiveness of therapeutic products. ” – Kenneth J.

Manufacturing

Scienmag

JUNE 18, 2025

In recent years, the intricate relationship between the gut microbiota and systemic health has become a focal point of biomedical research, linking microbial communities to a diverse spectrum of diseases. One of the central findings is that T_comm cells lose their stringent antigen specificity once licensed to infiltrate the CNS.

Immune Response

Pharmaceutical Technology

JUNE 26, 2025

This capability allows researchers to prioritize one billion molecules in as little as one day, compared to one million days with conventional methods. By prioritizing molecules for physics-based analyses, researchers can catch potential issues earlier in the drug discovery process, further enhancing efficiency and reducing costs.

Drugs

Bio Pharma Dive

JULY 22, 2025

Published July 22, 2025 • Updated 2 hours ago Delilah Alvarado Staff Reporter post share post print email license A sign bearing Sanofi's logo sits outside the company's U.S. An antibody drug, Beyfortus , that Sanofi developed with partner AstraZeneca has become a blockbuster product for preventing RSV disease in infants.

Vaccination

XTalks

DECEMBER 18, 2024

The most common form of CAH, 21-hydroxylase deficiency, disrupts hormone production, leading to cortisol deficiency and an overproduction of androgens. In 2018, the company also received approval for Orilissa (elagolix), which it licenses to AbbVie, for the treatment of endometriosis. billion in revenue by 2024.

Genetics

Pharmaceutical Technology

JULY 23, 2025

Find out more Introduced by the Medicines and Healthcare products Regulatory Agency (MHRA), it will allow patients to receive personalised treatments made at their hospital, clinic or near their homes. EU’s Pharma Package falls short of Europe’s goal of global competitiveness Why can’t the US figure out weight loss drug prices?

Manufacturing

XTalks

JULY 10, 2025

Potency assays play a vital role in biopharmaceutical development by measuring a drug candidate’s biological activity against a reference standard — offering essential insights into product quality and its potential clinical success. In early development, they support candidate selection and help optimize formulations.

Bioassay

Pharmaceutical Technology

JUNE 25, 2025

Over the past few decades, Alzheimer’s research and development (R&D) has seen a low success rate due to failure to demonstrate efficacy in clinical trials. In June 2024, Sanofi invested $40 million in Vigil Neuroscience, securing an exclusive right of first negotiation to license VG-3927.

Clinical Trials

Scienmag

JUNE 30, 2025

In a groundbreaking development poised to reshape the future of high-performance magnet manufacturing, United Rare Earths has successfully licensed two breakthrough technologies from Oak Ridge National Laboratory (ORNL). The adoption of these technologies by United Rare Earths signals a transformative shift in supply chain dynamics.

Licensing

Pharmaceutical Technology

JUNE 18, 2025

With the launch, Genomics claims its test is the first product in the country to be registered with the Medicines and Healthcare products Regulatory Agency (MHRA) and carry the UK Conformity Assessed (UKCA) mark, combining genetic testing and clinical data to enable prediction and prevention.

Genomics

XTalks

APRIL 3, 2025

More on the Lepodisiran Phase II Trial Lepodisiran is an investigational siRNA therapy that targets the production of apolipoprotein(a) (apo(a)) a key building block of Lp(a) to help reduce its levels in the body. Researchers randomized participants to receive varying doses of lepodisiran or a placebo.

Trials

XTalks

JUNE 25, 2025

UNAIDS has seen research that lenacapavir can be produced for just $40 per person per year, falling to $25 within a year of rollout. Drop the price, expand production and ensure the world has a shot at ending AIDS.” To address global access concerns, Gilead has announced a series of licensing and pricing initiatives.

FDA Approval

The Pharma Data

JUNE 24, 2025

Unlike traditional royalty deals, where investors purchase rights to a portion of revenue from marketed products, this synthetic royalty structure allows Royalty Pharma to provide upfront capital in exchange for a defined share of future revenue, subject to agreed terms and caps. Source link

Medicine

Pharmaceutical Technology

JULY 24, 2025

It’s not just about efficiency, it’s about creating space for better decisions and better outcomes,” says Walker Bradham, senior director of product management and design at Zelta. EU’s Pharma Package falls short of Europe’s goal of global competitiveness Why can’t the US figure out weight loss drug prices?

Clinical Trials

Pharmaceutical Technology

JULY 28, 2025

GlobalData forecasts that by 2034, pipeline products, including sonelokimab and povorcitinib will represent 47.3% As highlighted by GlobalData’s analysis, products that can safely intervene earlier in disease progression represent a significant commercial opportunity. of the total HS market.

Marketing

XTalks

JULY 23, 2025

As of now, 45 cellular and gene therapy products have received FDA approval, including 22 FDA-approved gene therapies and multiple examples targeting neuromuscular and central nervous system (CNS) disorders. Gene therapies are gaining traction as a promising approach for treating rare and complex neurological disorders.

Gene Therapy

Bio Pharma Dive

JULY 22, 2025

Published July 22, 2025 By BioPharma Dive staff post share post print email license Daniel Tadevosyan via Getty Images Today, a brief rundown of news involving Replimune Group and Johnson & Johnson, as well as updates from Omega Funds, iTeos Therapeutics and Roche that you may have missed. and European life sciences companies.

Gene Therapy

XTalks

JUNE 10, 2025

Sibeprenlimab is a monoclonal antibody that targets APRIL (A Proliferation-Inducing Ligand), which promotes the production of Gd-IgA1. By neutralizing APRIL, sibeprenlimab is designed to reduce the production of Gd-IgA1. “We In March 2025, Otsuka submitted a Biologics License Application (BLA) for sibeprenlimab.

Trials

Pharmaceutical Technology

JUNE 25, 2025

Fresh off a regulatory victory for a new HIV product, Gilead is shifting focus to the oncology space – signing a deal worth up to $750m to license a solid tumour treatment candidate from Kymera Therapeutics. Credit: Sundry Photography via Shutterstock. Sign up for our daily news round-up!

Drugs

Pharmaceutical Technology

JUNE 6, 2025

Juvenescence has acquired drug discovery company Ro5, a move that enhances its AI/machine learning capabilities and improves research and development capabilities. Credit: Collagery/Shutterstock. Thank you for subscribing View all newsletters from across the GlobalData Media network.

Drugs

Pharmaceutical Technology

JULY 21, 2025

Early collaborations Several pharmaceutical companies have begun exploring quantum computing through research partnerships and pilot projects. EU’s Pharma Package falls short of Europe’s goal of global competitiveness Why can’t the US figure out weight loss drug prices?

Protein

Pharmaceutical Technology

JUNE 25, 2025

The CDC’s capacity to monitor public health needs is critical, particularly as manufacturers navigate the intricate landscape of vaccine production and regulatory compliance. Reports Sustainability in Healthcare - Thematic Research Data Insights The gold standard of business intelligence.

Vaccination

Pharmaceutical Technology

JUNE 20, 2025

The Department of Health – Abu Dhabi (DoH) and Sanofi have signed a memorandum of understanding (MoU) to bolster vaccine development by leveraging local health-tech ecosystems and research infrastructure. The MoU was signed at the BIO International Convention 2025 in Boston, in the US state of Massachusetts.

Vaccination

Pharmaceutical Technology

JUNE 25, 2025

City of Hope National Medical Center’s radiology professor Phillip Kuo said: “The use of quantification in amyloid PET imaging has steadily moved from research to clinical practice, where it can aid in more confident and accurate diagnosis. Thank you for subscribing View all newsletters from across the GlobalData Media network.

Clinical Trials

Drug Patent Watch

DECEMBER 10, 2024

The Nature of Patent Thickets Patent thickets arise when multiple patents, often held by different companies, protect various aspects of a single technology or product. Cross-licensing agreements: To navigate patent thickets, many companies enter into cross-licensing agreements.

Licensing

Pharmaceutical Technology

JUNE 25, 2025

June 25, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook The research is supported by John Dimitri Research Foundation for Congenital Heart Disease and Big Hearts 2 Little Hearts. Credit: shisu_ka/Shutterstock. Thank you for subscribing View all newsletters from across the GlobalData Media network.

Clinical Trials

Pharmaceutical Technology

JUNE 25, 2025

Currently, patient data within Europe is managed on a country-to-country basis, which can create barriers to research. This legislation would abolish these barriers and could improve research and understanding of the prevalence and treatment of both common and rare diseases. The second of two panels on EHDS at HELTH Europe 2025.

Regulation

Scienmag

JULY 9, 2025

Their operations take place illegally or by means of legal agreements (governmental and/or private), such as payment for fishing permits or licenses, joint ventures, and chartering 8,9. Despite contributing significantly to food security and national fish production, SSF are often overlooked in fisheries policies. Letschert, J.,

Development

Pharmaceutical Technology

JUNE 18, 2025

GATC will cover all research and development costs for its assets while Lisata stands to earn milestone payments along with royalties from net sales upon successful product commercialisation. Should any assets identified by MAT be acquired by Lisata, GATC is entitled to receive licensing fees on a per-project basis.

Development

The Pharma Data

JUNE 24, 2025

Bayer and Tsinghua University Deepen Strategic Alliance to Advance Pharmaceutical Innovation in China Bayer and Tsinghua University (THU), two powerhouses in global pharmaceutical innovation and academic research, have announced a renewed commitment to their long-standing partnership.

Pharma R&D

Pharmaceutical Technology

JULY 22, 2025

Icotrokinra was co-discovered and is currently being developed through a licensing and collaboration agreement between Protagonist and J&J. EU’s Pharma Package falls short of Europe’s goal of global competitiveness Why can’t the US figure out weight loss drug prices?

FDA Approval

The Pharma Data

JULY 2, 2025

I’m grateful that Biogen is prioritizing this rare disease and advancing research that could ultimately change clinical practice.” The rights to felzartamab were licensed to Human Immunology Biosciences (HI-Bio) , which Biogen acquired in July 2024.

Trials

Bio Pharma Dive

JUNE 23, 2025

Ben explained that while these medications were first designed for blood sugar control, researchers quickly realized their powerful potential for weight loss. Expanding potential uses Emerging research suggests GLP-1 drugs might effectively treat chronic kidney disease, liver conditions, and certain cardiac diseases.

Gene Therapy

Pharmaceutical Technology

JUNE 19, 2025

Robert Barrie June 19, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook Both Kisunla and Leqembi are both approved by the Medicines and Healthcare products Regulatory Agency (MHRA), meaning they will still be available privately. AtlasStudio via Shutterstock.

Drugs

The Pharma Data

JUNE 24, 2025

Rather than diluting ownership or yielding developmental control to a larger pharmaceutical partner, Revolution Medicines is leveraging this funding arrangement to maintain autonomy over its research, development, and eventual commercialization efforts. This aligns both parties’ interests toward long-term success in the market.

Medicine

Pharmaceutical Technology

JUNE 18, 2025

Free Whitepaper Intensified Biomanufacturing of monoclonal antibodies Using an intensified fed-batch process is a viable alternative for higher protein production at a large scale without expanding the current manufacturing footprint. Syngene’s expertise in the field is covered in this white paper. You will receive an email shortly.

Clinical Trials

Pharmaceutical Technology

JUNE 17, 2025

From left-right: Selina Koch, PhD, Executive editor, head of intelligence and research, BioCentury; Renée Lucander, CEO, Hansa Biopharma; Christina Takke, managing partner, V-Bio Ventures; Matthew Foy, CEO, Avante Biocapital; and Jérôme Van Biervliet, PhD, managing director, VIB. The hubs in Europe are relatively more disparate.

Clinical Trials